DAJY(002030)2024-03-29 16:00Financial Performance - The company's operating revenue for 2023 was ¥1,180,897,087.04, a decrease of 90.20% compared to ¥12,046,135,040.64 in 2022[31]. - The net profit attributable to shareholders for 2023 was ¥104,659,624.06, down 98.07% from ¥5,412,341,064.13 in 2022[31]. - The net profit after deducting non-recurring gains and losses was -¥363,823,780.35, representing a decline of 107.03% compared to ¥5,176,134,506.67 in 2022[31]. - The basic earnings per share for 2023 was ¥0.0746, a decrease of 98.07% from ¥3.8565 in 2022[31]. - The total assets at the end of 2023 were ¥11,017,916,882.14, down 25.34% from ¥14,757,073,817.98 at the end of 2022[31]. - The net assets attributable to shareholders at the end of 2023 were ¥8,880,234,790.09, a decrease of 21.42% from ¥11,301,118,032.72 at the end of 2022[31]. - The weighted average return on equity for 2023 was 1.08%, down 57.88% from 59.64% in 2022[31]. - The cash flow from operating activities for 2023 was ¥780,111,104.70, a decline of 81.22% compared to ¥4,154,852,483.70 in 2022[31]. - The company reported a significant uncertainty regarding its ability to continue as a going concern, with net profits being negative for the last three accounting years[31]. - The revenue after deducting non-main business income for 2023 was ¥1,172,892,980.73, compared to ¥12,040,058,051.65 in 2022[31]. Shareholder Information - The company plans to distribute a cash dividend of 0.15 CNY per 10 shares to all shareholders, based on a total of 1,403,446,032 shares[4]. - The company’s major shareholder has been Guangzhou Guangyong Technology Development Co., Ltd. since April 28, 2006[15]. - The company has not disclosed any significant changes in its controlling shareholder or business operations since its establishment[15]. - The top ten unrestricted shareholders include Guangzhou Guangyong Technology Development Co., Ltd. with 233,391,995 shares, accounting for a significant portion of the total share capital[166]. - The company’s controlling shareholder, Guangzhou Guangyong Technology Development Co., Ltd., has a diverse range of business activities including investment and management consulting[172]. - The company has not engaged in any repurchase transactions among the top ten shareholders during the reporting period[171]. Business Operations - The company has not changed its main business since its listing, maintaining a focus on genetic testing and related services[15]. - The company has a continuous supervision responsibility from its appointed sponsor institution during the reporting period[16]. - The company has established a three-tier operational support system covering headquarters, provincial, and county levels to enhance market penetration[107]. - The company is actively pursuing international expansion strategies, leveraging its improved manufacturing capabilities and technology recognition in the global market[57]. - The company is expanding its business scope into various fields, including healthcare services, food safety, and industrial investment, thereby enhancing its overall market presence[61]. Research and Development - The company’s investment in research and development is aimed at driving growth in high-end diagnostic technologies and products, which are increasingly replacing lower-end solutions[56]. - The company has established a robust research and development platform, focusing on core materials and key processes to enhance product optimization and production capabilities[141]. - The company is investing in R&D for new technologies, aiming to release at least three innovative products in the next 12 months[95]. - The company has accelerated the development of molecular diagnostic technology platforms and is advancing product development across various diagnostic technology platforms, including immunology and biochemistry[141]. Market Trends - The IVD market is projected to maintain rapid growth, with the global market expected to exceed ¥100 billion, driven by new technologies and product applications[55]. - The domestic IVD market is anticipated to grow steadily, supported by medical reform and the shift towards preventive medicine, with molecular diagnostics emerging as the fastest-growing segment[55]. - The market for in vitro diagnostic products is experiencing significant growth due to the increasing demand for personalized testing in areas such as blood, tumors, and genetic diseases[58]. - The rapid development of POCT (point-of-care testing) products is creating substantial market opportunities due to their convenience and cost-effectiveness[58]. Product Development - The company has launched a series of major diagnostic products, including drug resistance gene testing kits and tumor personalized medication testing kits, with multiple approvals from the National Medical Products Administration[92]. - The company has received multiple regulatory approvals for its new product lines, enhancing its competitive edge in the market[93]. - The company is focused on expanding its market presence through the development of innovative diagnostic technologies and products[92]. - The company has reported a significant increase in revenue, with a year-over-year growth of 25% in the latest quarter, driven by higher demand for its testing products[65]. Financial Management - The company reported a significant difference between net cash flow from operating activities and net profit for the year, attributed to a decrease in operating receivables[123]. - The company has no long-term borrowings, indicating a conservative approach to debt management[131]. - The total amount of loans and advances was reported as ¥0.00, down from ¥23,130,222.66 in the previous year[181]. - The company has established a performance and incentive system based on operational goals, enhancing employee morale and work efficiency through a comprehensive reward system[147]. Corporate Social Responsibility - The company has actively participated in social responsibility activities, including donations to medical institutions and public health initiatives[148]. - In March 2023, the company donated RMB 950,000 to support the development of impoverished students and academic construction at the University of Science and Technology of China[148]. Future Outlook - The company anticipates continued growth in the next fiscal year, projecting a revenue increase of 15% to 20% based on current market trends and product demand[65]. - Future outlook includes continued investment in research and development to enhance product offerings and market reach[92]. - The company has set performance guidance for the upcoming fiscal year, projecting a revenue growth of approximately 15%[117].